Alnylam adds to hepatic pipeline

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) unveiled two new RNAi therapeutic candidates in its hepatic infectious diseases portfolio at the American Association for the Study of Liver Diseases (AASLD) meeting.

The company's ALN-HDV is designed to treat hepatitis delta virus (HDV) infection, and ALN-PDL targets hepatocyte-expressed programmed death ligand 1 ( PD-L1) to treat chronic liver infections. Both employ Alnylam's Enhanced Stabilization Chemistry (ESC)-GalNAc-conjugate technology. ...